

**TM STONEHAGE FLEMING
AIM FUND**



**ACTIVELY
MANAGED**



**STOCK PICKING
APPROACH**



**LONG-TERM
INVESTMENT HORIZONS**



**NAVIGATING TO INVESTMENTS
WITH CLEAR STRATEGIES**



**GROWTH
MINDSET**


INVESTMENT OBJECTIVE

The fund aims to achieve long-term capital growth.

INVESTMENT POLICY

The Fund aims to invest mainly in equities on the UK Alternative Investment Market ('AIM'). This will be achieved by an actively managed diversified portfolio of shares spread across any sector of AIM. In addition, the Fund may on occasion invest in fully listed shares of companies with smaller market capitalisations.

PORTFOLIO PERFORMANCE



8.92% TM SF AIM Fund B **-16.51%** Numis Alt Markets Index

PORTFOLIO COMMENTARY

It is usual for the stock market to rally on the run up to the end of the calendar year but December has seen UK indices drifting lower. The main reason is the uncertainty caused by the measures introduced by Rachael Reeves in her first budget in October. By far the most negative factor has been the rise in corporate National Insurance contributions. Companies with the largest labour force will be suffering the most and while many are able to mitigate partly the charge by increasing prices others could either implement a cost cutting programme or have contracts which cover inflationary costs. The net effect is likely to be some pressure on a rising inflation and increased unemployment. Already we have seen November inflation increase from 2.3% to 2.6% which has led the Bank of England Monetary Policy Committee to hold Bank Rate at 4.75% when a cut was previously wanted. Government borrowing costs (Gilt yields) have also increased which has also not helped the attraction of equities. However, the majority of smaller companies can act fairly promptly to pass on the costs but unfortunately, in some areas, there are bound to be casualties along the way. Another uncertainty is the effect on the global economy of the threatened trade tariffs when the Trump administration comes into power. Hopefully, the strong relationship between America and Great Britain will be maintained and the actual outcome might be better than some fear. In any case, much of this bad news is now discounted in the current stock market level and there may well be a good recovery in the early months of the new year as investors seek opportunities.

During the month we added to our holding in Altitude (promotional services) and Mission Group (advertising). We also started a new holding in Fevertree (soft drinks). The share price has fallen sharply after the company produced results which were below the optimistic market expectations. The company has been gaining market share in the regions it operates and, moving forward, is looking for overall growth of between 4% and 5%. The home UK market has been fairly flat but significant potential is expected from the US. To raise funds, we have reduced some of our larger holdings and decided to sell out of our holding in Quiz following its decision to de-list from AIM with a deteriorating outlook and a balance sheet which will require further refinancing. In summary, 2024 has been a disappointing year for the UK Stock Market and, as yet, the new Labour Government have done little to stimulate economic growth. However, much of the bad news is hopefully now disclosed and we would look for recovery from the current level and feel well placed and optimistic on an upturn.

FUND INFORMATION

KEY FACTS

Launch Date	5 October 2005
IA Sector	UK Smaller Companies
Fund Size	£61.8m
Dealing Frequency	Daily

MINIMUM INVESTMENT

Lump Sum	£50,000
Additional	£5,000
Regular Savings	N/A

FEES

Initial Charge	Up to 5.00%
Ongoing Charges Figure (OCF)*	0.67%
Annual Management Charge	0.60%

* The OCF is the management fee plus additional fund expenses (excluding transaction costs) as a percentage of the assets of the fund. This gives an indication of annual expenses which may vary over time.

CUMULATIVE FUND PERFORMANCE (%)

Performance	3m	6m	YTD	1yr	3yrs	5yrs
TM Stonehage Fleming AIM Fund B	-3.6	-8.4	-2.6	-2.6	-28.6	0.9
Numis Alternative Markets Index	0.5	-2.1	-1.1	-1.1	-36.7	-18.7

CALENDAR YEAR PERFORMANCE (%)

Performance	YTD	2023	2022	2021	2020	2019
TM Stonehage Fleming AIM Fund B	-2.6	-2.6	-12.8	-15.9	27.1	11.2
Numis Alternative Markets Index	-1.1	-1.1	-7.2	-31.1	7.6	19.3

Source: Morningstar as at 31/12/2024, % growth, total return, GBP, single price, UK net income reinvested with no initial charges.

PERFORMANCE DISCLOSURE

Past performance is not a guide to future performance. All investments risk the loss of capital. Investors may not get back the original amount invested. Income from investments may vary and is not guaranteed. Performance figures are net of fees and charges. For a full list of risks applicable to this fund, please refer to the Prospectus.

The fund holds a broad range of AIM listed companies and some of these carry a higher risk of failure and may be less liquid than shares listed on other exchanges. These shares may be also harder to sell quickly because of this lower liquidity. AIM listed companies may also experience greater price volatility which could also affect the value of the fund.

Source for all performance is Stonehage Fleming Investment Management Limited as at 31 December 2024. Total return (with dividends reinvested) is net of fees.

**TM STONEHAGE FLEMING
AIM FUND**

ENQUIRIES

ENQUIRIES AND DEALING	
0333 300 0375 (press 1 for Enquiries, press 2 for Dealing)	
DEALING:	
Thesis Unit Trust Management Limited, PO Box 3733, Royal Wootton Bassett, Swindon, SN4 4BG	
SEDOL CODES:	
Class B Share	B0JX3Z5
ISIN CODES:	
Class B Share	GB00B0JX3Z52
LIPPER IDS:	
Class B Share	65009655

SECTOR ALLOCATION (%)

Industrials	25.3
Information Technology	24.7
Health Care	18.8
Consumer Discretionary	10.1
Energy	9.6
Consumer Staples	6.0
Communication Services	5.5
Materials	2.6
Cash	1.4

TOP TEN HOLDINGS (%)

MS International Plc	8.0
Hargreaves Services	3.6
Supreme Plc	3.6
Netcall Plc	3.5
Venture Life Group Plc	3.0
Made Tech Group	2.5
Beximco Pharmaceuticals GDR regs	2.5
Advanced Medical Solutions	2.5
Alliance Pharma Plc	2.4
Tristel Plc	2.3

Source: Thesis Unit Trust Management Limited and Stonehage Fleming Investment Management Limited as at 31 December 2024. Third parties whose data may be included in this document do not accept any liability for errors or omissions.

OUTCOME OF FAIR VALUE ASSESSMENTS (2024)

Our assessment confirms:

- The fund meets the needs of the target market.
- The intended distribution strategy remains appropriate.
- The fund provides fair value to customers.

INVESTOR PROFILE

The fund is appropriate for all investor types, including those with only a basic knowledge of funds. It is compatible with investors who do not need a capital guarantee (investors must be prepared to accept fluctuations in the value of capital, including the ability to bear 100% capital loss) and are seeking capital growth. Due to the volatility of markets, investors should be willing to accept price fluctuations in exchange for the opportunity of potentially higher returns. This is a long term investment and investors should have an investment time horizon of at least 5 years. The recommended holding period does not provide any guarantee that the objective will be achieved. This product is eligible for all distribution channels (e.g. investment advice, portfolio management, non-advised sales and pure execution services).

The fund is unlikely to be appropriate for those who:

- Are looking for full capital protection or full repayment of the amount invested, and those who want a guaranteed return
- Have no risk tolerance
- Who are unwilling to accept price fluctuations (volatility) in the value of the fund
- Do not intend to invest for the long term

IMPORTANT INFORMATION

This is a marketing communication issued by Stonehage Fleming Investment Management Limited (SFIM). SFIM is the investment manager of the Fund. All investments risk the loss of capital. No guarantee or representation is made that the funds will achieve their investment objective. The value of investments may go down as well as up. For products designed to return income, the distributions can also go down or up and you may not receive back the full value of your initial investment. Derivatives have not been used but are allowed if appropriate for efficient asset management. The Fund only invests in UK assets but is allowed to hold shares on overseas exchanges. This would occur in the event of a company delisting from the London stock market and would not be expected to be material. Hence, there would be limited foreign exchange risk. Past performance is not a guide to future returns. If the information is not displayed in your base currency, then the return may increase or decrease due to currency fluctuations. The distribution or possession of this document in jurisdictions outside the United Kingdom may be restricted by law or other regulatory requirements. For details of the Funds investment policy, please see the Investment Objective and Policy section of the Fund Prospectus Document.

FUND MANAGERS



PAUL MUMFORD

Paul Mumford began his career in 1963 working initially as an Analyst for Norris Oakley Brothers and later as a smaller companies expert at R Nivison. Paul moved to fund management in 1988 when he joined Glenfriars. Paul then joined Cavendish Asset Management at the group's formation in 1994 and funds were launched. The group was subsequently acquired by Stonehage Fleming in July 2020. Paul is the co-manager of the TM Stonehage Fleming AIM Fund and the TM Stonehage Fleming Opportunities Fund.



NICK BURCHETT

Nick Burchett began his career in 1983 at Strauss Turnbull and subsequently joined W.I. Carr in 1990 which later became Investec Wealth & Investment after a number of mergers and acquisitions. Nick dealt extensively with portfolios of UK equities, markets and execution strategies. After 27 years at Investec he joined Cavendish Asset Management in November 2017 to jointly manage this fund. The acquisition of Cavendish Asset Management was subsequently made by Stonehage Fleming in July 2020. Nick is the co-manager of the TM Stonehage Fleming AIM Fund and the TM Stonehage Fleming Opportunities Fund.

AWARDS



Whilst every effort is made to ensure that the information provided to clients is accurate and up to date, some of the information may be rendered inaccurate by changes in applicable laws and regulations may be subject to change in the future. The information in this document does not constitute legal, tax, or a personal recommendation.

United Kingdom (UK): The Fund is recognised by the Financial Conduct Authority (FCA) for promotion to retail and professional investors in the UK.

The Authorised Fund Manager is Thesis Unit Trust Management Limited, Exchange Building, St John's Street, Chichester, West Sussex, PO19 1UP. Authorised and regulated by the Financial Conduct Authority. Before you invest you should read the Key Investor Information Document (KIID) and the Prospectus which contain detailed information. These documents are available in English, free of charge, upon request by writing to Thesis Unit Trust Management Limited at Exchange Building, St John's Street, Chichester, West Sussex PO19 1UP; or by phoning 01483 783 900 between 9am and 5pm Monday to Friday; or on the website at www.tutman.co.uk/literature/

© Stonehage Fleming Investment Management Limited 2024

STONEHAGE FLEMING INVESTMENT MANAGEMENT LIMITED

6 St James's Square London SW1Y 4JU United Kingdom t: +44 20 7087 0000 e: enquiries@stonehagefleming.com

Authorised and Regulated by the Financial Conduct Authority (FRN: 194382). Registered Company No. 4027720 England & Wales

www.stonehagefleming.com/investments